Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, PH 16-69, 622 West 168th Street, New York, NY 10032, United States.
Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, PH 16-69, 622 West 168th Street, New York, NY 10032, United States.
Contraception. 2018 Sep;98(3):199-204. doi: 10.1016/j.contraception.2018.05.005. Epub 2018 May 9.
To compare transabdominal sonography (TAS) to transvaginal sonography (TVS) in medical abortion eligibility assessment, specifically to measure how often clinicians chose to order additional testing for eligibility assessment following TAS and TVS, and to look for differences by patient and clinician characteristics. Also, to compare patient acceptability between the two modalities.
This pragmatic multisite randomized noninferiority trial compared TAS to TVS at 10 New York City and New Jersey health centers that provide medical abortion. Women seeking medical abortion were randomized 1:1 to receive TAS or TVS. Following the study ultrasound examination, clinicians determined whether participants were eligible for medical abortion based on these results or warranted further testing. All participants completed an acceptability questionnaire. We compared additional testing and acceptability between TAS and TVS.
Of those randomized to TAS, 63/317 (19.9%) received additional testing compared to 15/312 (4.8%) randomized to TVS. After TAS, most additional testing consisted of a same-day TVS. Other tests included β-hCG testing, scheduled repeat sonography or return visit. After TAS, 13.4% seen by physicians and 27.6% seen by advanced practice nurses (APNs) received additional testing (p<.01). Additional testing was more common in early gestational ages for both groups. We enrolled too few women with a body mass index (BMI) >35 kg/m to make comparisons. Participants found TAS more acceptable than TVS, and two thirds preferred TAS for future care.
TAS provided sufficient information for clinicians to assess medical abortion eligibility without additional tests for most patients. However, the frequency of additional testing was exceedingly close to our predefined noninferiority boundary. Why APNs ordered substantially more additional testing than physicians is unclear. TAS was more acceptable to patients than TVS.
TVS use requires high-level disinfection, which is resource-intensive and thus can be a barrier to care. Instead, TAS can be first-line for most women, reducing resources needed to provide medical abortion. Further research could help to establish gestational age and BMI thresholds beyond which TVS would be a more informative first test. We also need to evaluate whether additional training in using TAS would decrease additional testing.
比较经腹部超声(TAS)与经阴道超声(TVS)在药物流产适应证评估中的作用,具体来说,就是评估在进行 TAS 和 TVS 后,临床医生为了进一步评估适应证而选择进行额外检查的频率,并寻找与患者和临床医生特征相关的差异。同时,比较两种方式的患者接受度。
本项在纽约市和新泽西州的 10 家提供药物流产服务的健康中心开展了一项实用、多中心、随机、非劣效性试验,比较了 TAS 与 TVS 的作用。接受药物流产的女性被 1:1 随机分为 TAS 组或 TVS 组。在研究性超声检查后,临床医生根据这些结果判断参与者是否适合药物流产,或是否需要进一步检查。所有参与者均完成了一份接受度问卷。我们比较了 TAS 和 TVS 之间的额外检查和接受度。
与 TVS 组相比,随机分配至 TAS 组的 317 名女性中有 63 名(19.9%)接受了额外检查,而随机分配至 TVS 组的 312 名女性中有 15 名(4.8%)接受了额外检查。在 TAS 之后,大多数额外检查为当天的 TVS。其他检查包括β-hCG 检测、预约复查超声或复诊。在 TAS 之后,接受检查的医生中有 13.4%和高级执业护士(APN)中有 27.6%(p<.01)建议进行额外检查。对于两组患者,在早期妊娠阶段,额外检查更为常见。由于纳入的 BMI>35kg/m²的女性数量太少,我们无法进行比较。与 TVS 相比,参与者发现 TAS 更易于接受,有三分之二的人表示未来更愿意接受 TAS 治疗。
TAS 提供了足够的信息,使临床医生能够评估大多数患者的药物流产适应证,而无需进行额外检查。然而,额外检查的频率非常接近我们预设的非劣效性边界。为什么 APN 建议进行的额外检查比医生多很多,目前尚不清楚原因。与 TVS 相比,TAS 更受患者欢迎。
TVS 需要高水平消毒,这需要大量资源,因此可能成为阻碍护理的因素。相比之下,TAS 可以成为大多数女性的一线检查方法,从而减少提供药物流产所需的资源。进一步的研究可以帮助确定除了目前的妊娠龄和 BMI 阈值外,哪些情况下 TVS 作为首次检查会提供更有价值的信息。我们还需要评估在使用 TAS 方面进行额外培训是否会减少额外检查。